Kurse werden geladen...
Prognose
Das durchschnittliche Kursziel der Analysten beträgt 5,16€(+616,67%). Der Median liegt bei 5,16€(+616,67%).
Kaufen | 5 |
Halten | 7 |
Verkaufen | 2 |
Scoring-Modelle
Dividenden-Strategie | 0 / 15 |
HGI-Strategie | 14 / 18 |
Levermann-Strategie | -2 / 13 |
News
Data Demonstrating Sotagliflozin Reduces the Risk of Clinically Important Hypoglycemic Events in Adults with Type 1 Diabetes When Added to Insulin Presented at the 85th Scientific Sessions of the American Diabetes Association (ADA)
Oral presentation highlighted the post-hoc analysis during the “Interventions to Prevent Hypoglycemia: Bench to Bedside” session Treatment with sotagliflozin resulted in no increased risk and a reduction in hypoglycemia events, particularly in patients with blood glucose ≤55 mg/dL THE WOODLANDS, Texas, June 23, 2025 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) announced that a post-hoc analysis of clinical study data showing a reduction in hypoglycemic events when sotagliflozin was added to optimized insulin therapy for people with type 1 diabetes (T1D) was presented yesterday during the 85th Scientific Sessions of the American Diabetes Association (ADA) in Chicago, Illinois. The ADA emphasizes that hypoglycemia remains an important patient management issue in T1D.» Mehr auf globenewswire.com
Lexicon to Present Data at the 85th Scientific Sessions of the American Diabetes Association (ADA)
THE WOODLANDS, Texas, June 18, 2025 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that data from a study evaluating the impact of sotagliflozin on hypoglycemia in people with type 1 diabetes will be delivered as an oral presentation on Sunday, June 22, during the 85th Scientific Sessions of the American Diabetes Association (ADA). At the meeting, the company will also present topline data from its PROGRESS Phase 2b study evaluating pilavapadin (LX9211) in adults with diabetic peripheral neuropathic pain.» Mehr auf globenewswire.com
Lexicon Pharmaceuticals to Present at the 2025 Jefferies Global Healthcare Conference
THE WOODLANDS, Texas, May 29, 2025 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that Company management will participate in a fireside chat at the 2025 Jefferies Global Healthcare Conference, taking place in New York City on Thursday, June 5 at 12:50 p.m. ET. The live event and a replay of the presentation can be accessed via the Events page of the Company's website at https://investors.lexpharma.com/.» Mehr auf globenewswire.com
Historische Dividenden
Alle Dividenden KennzahlenUnternehmenszahlen
(EUR) | März 2025 | |
---|---|---|
Umsatz | 1,17 Mio | 11,41% |
Bruttoeinkommen | 1,14 Mio | 28,70% |
Nettoeinkommen | −23,38 Mio | 47,86% |
EBITDA | −23,74 Mio | 42,37% |
Fundamentaldaten
Metrik | Wert |
---|---|
Marktkapitalisierung | 240,46 Mio€ |
Anzahl Aktien | 363,18 Mio |
52 Wochen-Hoch/Tief | 2,11€ - 0,24€ |
Dividenden | Nein |
Beta | 1,01 |
KGV (PE Ratio) | −1,57 |
KGWV (PEG Ratio) | −0,08 |
KBV (PB Ratio) | 2,26 |
KUV (PS Ratio) | 8,95 |
Unternehmensprofil
Lexicon Pharmaceuticals, Inc. ist ein biopharmazeutisches Unternehmen, das sich auf die Entdeckung, Entwicklung und Vermarktung von pharmazeutischen Produkten konzentriert. Seine oral verabreichten niedermolekularen Arzneimittelkandidaten, die sich in der Entwicklung befinden, umfassen Sotagliflozin, das die klinischen Studien der Phase III zur Behandlung von Herzinsuffizienz und Typ-1-Diabetes abgeschlossen hat, und LX9211, das sich in der klinischen Entwicklung der Phase II zur Behandlung von neuropathischen Schmerzen befindet. Das Unternehmen hat strategische Kooperations- und Lizenzvereinbarungen mit Bristol-Myers Squibb Company und Genentech, Inc. Lexicon Pharmaceuticals, Inc. wurde 1995 gegründet und hat seinen Hauptsitz in The Woodlands, Texas.
Name | Lexicon Pharmaceuticals |
CEO | Dr. Michael S. Exton Ph.D. |
Sitz | The Woodlands, tx USA |
Website | |
Industrie | Chemikalien |
Börsengang | |
Mitarbeiter | 103 |
Ticker Symbole
Börse | Symbol |
---|---|
NASDAQ | LXRX |
Frankfurt | LX31.F |
Assets entdecken
Shareholder von Lexicon Pharmaceuticals investieren auch in folgende Assets